Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Abou-El-Enein, Mohamed  [Clear All Filters]
2023
Choe JH, Yu T, Abramson JS, Abou-El-Enein M. Cost-Effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood Adv. 2023.
Elsallab M, Ellithi M, Hempel S, Abdel-Azim H, Abou-El-Enein M. Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis. Cancer Gene Ther. 2023.
2022
Landwehr-Kenzel S, Mueller-Jensen L, Kuehl J-S, Abou-El-Enein M, Hoffmann H, Muench S, Kaiser D, Roemhild A, von Bernuth H, Voeller M, et al. Adoptive transfer of ex vivo expanded regulatory T-cells improves immune cell engraftment and therapy-refractory chronic GvHD. Mol Ther. 2022.
Choe JH, Abdel-Azim H, Padula WV, Abou-El-Enein M. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. JAMA Netw Open. 2022;5(12):e2245956.
Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, Abou-El-Enein M. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2022.
2021
Master Z, Matthews KRW, Abou-El-Enein M. Unproven stem cell interventions: A global public health problem requiring global deliberation. Stem Cell Reports. 2021;16(6):1435-1445.
2018
Bauer G, Elsallab M, Abou-El-Enein M. Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions. Stem Cells Transl Med. 2018.
2016
Abou-El-Enein M, Elsanhoury A, Reinke P. Overcoming Challenges Facing Advanced Therapies in the EU Market. Cell Stem Cell. 2016;19(3):293-297.